Abstract
Cell migration plays a pivotal role in a many biological process that are essential for development, repair, and pathogenesis. Thus, inhibition of migration has the potential of limiting or suppressing the development of various diseases. Much of the focus on the therapeutic treatment of cancer has involved compounds that target cell proliferation and subsequent cell death. However, targeting migration is another approach that has not been pursued but holds promise for alternative means of therapy. One such potential therapeutic is a small protein that inhibits the migration of a number of cell types. This protein is derived from the amino terminal end of the 24 kDa form of fibroblast growth factor, and suppresses migration in the presence of a variety of growth factors. Analysis of the protein in mouse models shows that it inhibits in vivo angiogenesis and tumor growth at low concentrations. Thus, inhibition of migration is a viable alternative to more traditional methods of therapeutically treating tumors. Further study of the mechanism of inhibition can lead to the development of novel drugs targeting a distinctive cell process.
Keywords: cell migration, protein inhibitors, fibroblast growth factor-2, angiogenesis, alternative translation, metastasis
Current Cancer Drug Targets
Title: Cancer Therapy Through Control of Cell Migration
Volume: 5 Issue: 7
Author(s): Eugene G. Levin
Affiliation:
Keywords: cell migration, protein inhibitors, fibroblast growth factor-2, angiogenesis, alternative translation, metastasis
Abstract: Cell migration plays a pivotal role in a many biological process that are essential for development, repair, and pathogenesis. Thus, inhibition of migration has the potential of limiting or suppressing the development of various diseases. Much of the focus on the therapeutic treatment of cancer has involved compounds that target cell proliferation and subsequent cell death. However, targeting migration is another approach that has not been pursued but holds promise for alternative means of therapy. One such potential therapeutic is a small protein that inhibits the migration of a number of cell types. This protein is derived from the amino terminal end of the 24 kDa form of fibroblast growth factor, and suppresses migration in the presence of a variety of growth factors. Analysis of the protein in mouse models shows that it inhibits in vivo angiogenesis and tumor growth at low concentrations. Thus, inhibition of migration is a viable alternative to more traditional methods of therapeutically treating tumors. Further study of the mechanism of inhibition can lead to the development of novel drugs targeting a distinctive cell process.
Export Options
About this article
Cite this article as:
Levin G. Eugene, Cancer Therapy Through Control of Cell Migration, Current Cancer Drug Targets 2005; 5 (7) . https://dx.doi.org/10.2174/156800905774574048
DOI https://dx.doi.org/10.2174/156800905774574048 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nucleic Acids Delivery Systems: A Challenge for Pharmaceutical Technologists
Current Drug Metabolism Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Current Drug Targets Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology:Theory, Data Acquisition,Analysis, and Examples
Current Medical Imaging Working Towards the Development of Vaccines for the Treatment and Prevention of Early Breast Cancer
Current Cancer Therapy Reviews An Updated Portrait of Pathogenesis, Molecular Markers and Signaling Pathways of Hepatocellular Carcinoma
Current Pharmaceutical Design Metabolomics as a Tool for Drug Discovery and Personalised Medicine. A Review
Current Topics in Medicinal Chemistry Nanomaterials for Photohyperthermia: A Review
Current Pharmaceutical Design T Cell Costimulatory and Inhibitory Receptors as Therapeutic Targets for Inducing Anti-Tumor Immunity
Current Cancer Drug Targets Development of Lymphatic Vessels: Tumour Lymphangiogenesis and Lymphatic Invasion
Current Medicinal Chemistry Liposome Encapsulated All Trans Retinoic Acid (ATRA) has Enhanced Immunomodulatory and Inflammation Reducing Activities in Mice Model
Anti-Cancer Agents in Medicinal Chemistry P2X7 Receptor-Associated Programmed Cell Death in the Pathophysiology of Hemorrhagic Stroke
Current Neuropharmacology Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma
Recent Patents on Anti-Cancer Drug Discovery Eplerenone, a New Selective Aldosterone Blocker
Current Pharmaceutical Design Antiangiogenic Therapy for High-Grade Gliomas
CNS & Neurological Disorders - Drug Targets Drug-Drug Interactions of Triazole Antifungal Agents in Multimorbid Patients and Implications for Patient Care
Current Drug Metabolism Editorial (Thematic Issue: Medicinal Inorganic Chemistry: Identification of New Targets in Drug Discovery)
Current Topics in Medicinal Chemistry Nanoliposome is a Promising Carrier of Protein and Peptide Biomolecule for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Pharmacokinetics and Acute Toxicity of a Histone Deacetylase Inhibitor, Scriptaid, and its Neuroprotective Effects in Mice After Intracranial Hemorrhage
CNS & Neurological Disorders - Drug Targets Bridging the Gap: The Potential Role of Corticosteroid Binding Globulin in Cardiac Steroid Facilitation
Current Drug Targets Receptor Tyrosine Kinase Kit and Gastrointestinal Stromal Tumours: An Overview
Current Medicinal Chemistry